Cancer Advances logo.jpg
Cancer Advances, Inc. Announces Issuance of New U.S. Patent
28 févr. 2023 02h00 HE | Cancer Advances Inc
DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S....
Roots-Analysis-Logo.png
The opportunity within the regulatory T-cell therapies market is projected to grow at an annualized rate of ~45%, till 2035, claims Roots Analysis
09 mars 2022 09h30 HE | Roots Analysis
London, March 09, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Regulatory T-Cell (Tregs) Therapies Market, 2021 – 2035” report to its list of offerings. Given the various...
Cancer Advances logo.jpg
Cancer Advances, Inc. Announces Publication, “Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model" in Cancer Prevention Research
24 août 2021 10h30 HE | Cancer Advances Inc
DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces a new publication in...
Teneo_logo_FINAL_whitebkgnd.png
Teneobio’s Clinical Candidate, TNB-409, is a Selective IL-2 Receptor Bispecific Agonist for the Treatment of Solid Tumors
19 mai 2021 08h00 HE | TeneoBio, Inc
NEWARK, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies,...
Cancer Advances logo.jpg
Cancer Advances, Inc. Announces Poster Presentation at ASCO GI
21 janv. 2020 22h20 HE | Cancer Advances Inc
DURHAM, N.C., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, will present a poster at the...
Key Patent Issued on Qantu's QT-0101 Adjuvant
25 févr. 2019 05h00 HE | QANTU Therapeutics, Inc.
LEWISVILLE, Texas, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Qantu Therapeutics, Inc. announces the issuance of United States patent 10,195,257 titled “Vaccine Formulations Comprising Quillaja...